← Back to catalogue
Research draft

glioblastoma

vr.tr.glioblastoma · XCT.STA

Let an agent explain glioblastoma in general terms from neuro-oncology guidelines, describe symptoms, diagnosis, classification and treatment, relay outcomes and research with attribution, and route personal questions to clinicians.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain glioblastoma in general terms from neuro-oncology guidelines, describe symptoms, diagnosis, classification and treatment, relay outcomes and research with attribution, and route personal questions to clinicians.

The most common and most aggressive primary malignant brain tumour in adults, a grade 4 astrocytoma arising from glial cells, most often in the cerebral hemispheres and rarely in the cerebellum, defined since 2021 by IDH-wildtype status and molecular features, with histological variants such as giant cell glioblastoma and expression subtypes described as classical, proneural, mesenchymal and neural; glioblastoma is treated with surgery, radiotherapy and temozolomide chemotherapy, with median survival of about 15 months and active research into new therapies.

What it is for: Not applicable; a cancer.

It can be explain the tumour and classification; relay symptoms and diagnosis; relay treatment and outcomes; route personal questions.

Distinguishing features

Highest grade glioma

IDH-wildtype definition

Infiltrative growth

Poor prognosis

What it looks like

Not a visible object; a brain tumour seen on MRI.

Physical character

incidence: about 3-4 per 100000 per year

median survival: about 15 months - with standard treatment

median age at diagnosis: about 64 years

How it is recognised

Grade 4 astrocytoma of the brain

IDH-wildtype glioblastoma; giant cell variant; classical, proneural, mesenchymal and neural subtypes; cerebellar glioblastoma

Lower-grade astrocytomas and IDH-mutant tumours are classified separately; brain metastases are not primary tumours

Related models

is a kind of - in registry terms

astrocytoma

is classified by - 2021 edition

WHO classification of CNS tumours

is treated with - and radiotherapy

temozolomide

is defined by - status

IDH-wildtype

In practice

Families and kinds

IDH-wildtype glioblastoma

histological variants such as giant cell, gliosarcoma and epithelioid glioblastoma

expression subtypes: classical, proneural, mesenchymal and neural

cerebellar and other uncommon sites

paediatric high-grade gliomas as related but distinct tumours

Identifiers

ICD-11 2A00.0 gliomas of brain

ICD-O 9440/3 glioblastoma

MeSH D005909 glioblastoma

Standards and regulation

WHO 2021 classification of CNS tumours

EANO and NCCN neuro-oncology guidelines

Drug and device approvals such as tumour treating fields

Failure modes and hazards

Agents giving personal medical advice

Overstating unproven therapies

Confusing with lower-grade or metastatic tumours

Stale classification

Also called

cerebellar glioblastomaglioblastoma classical subtypeglioblastoma proneural subtypeglioblastoma mesenchymal subtypeglioblastoma neural subtypegiant cell glioblastomasecondary glioblastoma multiformeGiant-cell glioblastomagliosarcoma

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Help Getting help first.

Safety.

Signs

Warning signs.

Signs

Signs.

  1. What signs such as new seizures, persistent headache, weakness or personality change need prompt assessment? action
  2. Is the user describing such signs, which need urgent medical care? boundary

Care

Specialist care.

Care

Care.

  1. How is glioblastoma diagnosed and classified by neuro-oncology teams, in general terms? provenance
  2. Is the user asking about their own or a relative diagnosis, which needs the oncology team? boundary
Understand The tumour.

Clinical.

Definition

Definition and classification.

Definition

Definition.

  1. What is glioblastoma, and how do IDH status, histological variants and expression subtypes define it? definition
  2. Is the question about glioblastoma or another brain tumour? boundary

Biology

Biology.

Biology

Biology.

  1. Why is glioblastoma so aggressive, and what molecular features such as MGMT methylation matter? provenance
  2. Which entry fits the specific marker? action
Treat Treatment and outlook.

Clinical.

Treatment

Treatment.

Treatment

Treatment.

  1. What treatments do guidelines recommend, from surgery and radiotherapy to temozolomide and tumour treating fields, in general terms? provenance
  2. Which references are standard? provenance

Outlook

Outcomes and support.

Outlook

Outlook.

  1. What outcomes are seen, and what supportive and palliative care exists? provenance
  2. Which sources are cited? provenance
Context Research and support.

Context.

Research

Research.

Research

Research.

  1. What research addresses immunotherapy, targeted therapy and trials, with findings attributed? provenance
  2. Which entry fits neuro-oncology research? action

Support

Support.

Support

Support.

  1. What organisations support patients and families? provenance
  2. Which entry fits the specific organisation? action

What the second pass must settle

  • Should astrocytoma and IDH-mutant glioma be separate primary entries?
  • How should neuro-oncology guidelines be linked?
  • The registry entry has merged aliases naming subtypes and sites; should they be split off?